Jul. 7 at 3:26 PM
Full Alzheimer Disease Analyze:
If
$PMN can use its blinded data to demonstrate that it can achieve the same therapeutic effect as Leqembi or Kisunla without the associated side effects, the stock is poised for extremely dynamic catch-up growth relative to these multi-billion-dollar corporations.
$BIIB Drug: Leqembi®️ (lecanemab) FDA-approved. Issue: Slows cognitive decline by approximately 27% but carries the well-known, high ARIA safety risk (approx. 13% incidence of brain swelling in studies).
$LLY Kisunla FDA-approved. Issue: Slows decline by up to 35% but has the highest ARIA rate on the market due to its biological mechanism.
Phase 3 drugs:
$RHHBY Trontinemab Status is a highly sophisticated antibody utilizing "brain shuttle" technology.
$AXSM Auvelity FDA expanded approval to include the treatment of agitation associated with AD.
$ AVXL Blarcamesine Phase 3 completed. Not an antibody, but an oral tablet.
A completely different biological pathway compared to
$PMN!
